IL13 and conjunctivitis: However, data from the phase 3 trials programme with tralokinumab, which also specifically neutralises IL‐13, has reported a 2–3 fold increase in conjunctivitis versus placebo (7.5% vs. 3.2; hazard ratio 2.4 [95% CI 1.5,3.8]),28, 29 providing evidence that argues against IL‐4 being the sole driver of conjunctivitis.30